Back to YC Companies
Invitris
Winter 2023
Active
Creating new protein-based drugs at scale
6 people View on YC
Invitris at a glance
- Y Combinator batch
- Winter 2023
- Status
- Active
- Industry
- Healthcare
- Team size
- 6 people
- Location
- Not recorded
- Website
- Not recorded
Every field above comes from the Y Combinator company record. Nothing is estimated.
About Invitris
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
Tags:
Biotech
Nanotechnology
Drug discovery